Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.90 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.90 |
| ▸ | ATM | Q13315 | 1/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.78 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.67 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.67 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227976 | 0.98 | LTA4H (0.87) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL5116881 | 0.98 | LTA4H (0.87) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL227425 | 0.98 | LTA4H (0.87) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL5117118 | 0.96 | LTA4H (0.84) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL5139685 | 0.96 | LTA4H (0.84) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL18824776 | 0.91 | ATM (0.87) | LTA4HPTGS2ATML3MBTL1KDM4E | |
| SCHEMBL7139221 | 0.91 | LTA4H (0.75) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL491581 | 0.89 | ATM (0.90) | LTA4HPTGS2ATML3MBTL1HRH3 | |
| SCHEMBL1776837 | 0.89 | ATM (0.90) | LTA4HPTGS2ATML3MBTL1HRH3 | |
| SCHEMBL5856455 | 0.88 | ATM (0.88) | LTA4HPTGS2ATML3MBTL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0527186-A4 | — | UNIV ILLINOIS (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0527186-A1 | PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS | The Board of Trustees for the University of Illinois (US) | 1993-02-17 | — | — | EP | claimed |
| WO-1991016820-A1 | PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1991-11-14 | — | — | WO | claimed |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-113993872-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-3986896-B1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-113993872-A | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020254572-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |
| CN-105753768-B | Production method of single nitrogen heterocyclic compound | 北京恒瑞新霖科技有限公司 | 2020-11-27 | — | — | CN | disclosed |
| WO-1997014671-A1 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | disclosed |
| US-5552412-A | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis | PFIZER INC (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1996021656-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
| US-5459139-A | Antitumor agents, anticholesterol agents, antiestrogens, treatment of breast cancer | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1995-10-17 | — | — | US | disclosed |
| US-5354861-A | Binds to antiestrogen binding sites; antiproliferative activity | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1994-10-11 | — | — | US | disclosed |
| US-5242892-A | With 5-aminolevulinic acid | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1993-09-07 | — | — | US | disclosed |
| US-4383998-A | Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 1983-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | LTA4H 4750/4885PTGS2 2952/4885ATM 191/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | LTA4H 4810/4885PTGS2 2959/4885ATM 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.